Highlights

  • XanaMIA achieved database lock in October 2026.
  • Topline final trial results were scheduled for mid-November 2026.
  • The September-quarter report recorded cash of $15.9 million.
  • An R&D tax incentive receipt of $10.8 million was announced in October.

Actinogen Medical Limited (ASX:ACW) is a biotechnology developer investigating Xanamem, an oral treatment designed to modulate cortisol activity in the brainThe company’s latest clinical updates centre on the XanaMIA Alzheimer’s disease study, which reached database lock in October ahead of a planned mid-November 2026 topline results announcement.

XanaMIA Reaches a Reporting Milestone

Database lock means the study dataset has reached a stage where the information is fixed for the planned analysis. It does not disclose the efficacy outcome. The company’s 21 October announcement narrowed the anticipated timing of the readout, following completion of the final participant visit in late September.

The XanaMIA Phase 2b/3 study enrolled 247 patients with mild to moderate Alzheimer’s disease. It compares Xanamem with placebo during a 36-week treatment period. The principal assessment uses the Clinical Dementia Rating Scale – Sum of Boxes, a recognised measurement of disease-related clinical change.

Clinical Development and Extension Study

(ASX:ACW) describes Xanamem as an inhibitor of 11β-HSD1, an enzyme involved in regulating cortisol within the brain. The rationale is that modifying brain cortisol may affect neurological disease processes. That biological explanation is a development hypothesis; the pivotal trial’s findings are needed to establish whether the investigational treatment meets its defined outcomes.

The company also conducts an open-label extension of the XanaMIA trial, in which participating patients receive active Xanamem rather than a blinded assignment. In its September quarterly update, Actinogen reported 160 patients receiving treatment in the extension and an 87% rollover rate for eligible main-trial participants entering directly.

An open-label extension can help gather further safety and observational information, but its design differs from a randomised, placebo-controlled comparison. It therefore does not replace the pivotal trial’s primary statistical analysis. Actinogen indicated that available extension data would also be considered when the topline results were reviewed.

The study has previously passed an independent safety and futility review. Such an assessment allows the trial to continue under specified monitoring conditions; it should not be confused with final proof of clinical benefit. The trial’s pending topline result remains a separate event for (ASX:ACW).

Funding, Research Rebate and Next Steps

For the quarter ended 30 September 2026, (ASX:ACW) reported cash of $15.9 million. Its quarterly announcement also described approximately $5.3 million received from the exercise and underwriting of unlisted options. During the quarter, operating expenditure was $6.2 million, with clinical trial activity accounting for much of the spending.

On 26 October 2026, the company announced receipt of a $10.8 million research and development tax incentive rebate. The earlier quarterly report had anticipated around $6 million of net cash after repayment of borrowing advanced against that rebate. The gross rebate and expected net cash impact are different measures.

Actinogen has described further regulatory planning and potential development partnerships as priorities after the XanaMIA readout. These are company intentions rather than completed regulatory approvals or binding collaboration agreements. Any later study requirements would depend on results and discussions with relevant authorities.

The disclosures of (ASX:ACW) bring together a defined clinical milestone, patient participation in an extension study and the cash resources reported during 2026. The mid-November readout was not yet available as of 30 October 2026, so no efficacy conclusion can be drawn from the timing announcement alone.

Key Insights

Actinogen’s October database-lock notice confirms that a pivotal Alzheimer’s disease trial reached its planned analysis stage, while the quarterly report details clinical activity and cash. For (ASX:ACW), the completed milestone and the pending clinical outcome remain separate facts.